ScholarWorks@Hanyang University: Won, Young Woong

Detailed Information

Won, Young Woong (원영웅)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 혈액종양내과

Tel 031-560-2163
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:3||Nonsmall cell lung cancer:3||s lymphoma:2||cell cycle:2||cell signaling:2||Palliative care:2||Withholding treatment:2||telomere:2||colon cancer:2||Risk factor:2||Chemotherapy:2||Treatment:2||Survival:2||KML001:2||Lifesustaining treatment:2||Breast cancer:1||Cancer deaths:1||Cell signal:1||Chloroquine:1||Chronic myeloid leukemia:1||Cisplatin:1||Clear cell adenocarcinoma:1||Coronary angiography:1||Dasatinib:1||Deauville scores:1||Decisions:1||Decitabine:1||Deferasirox:1||Diffuse large B cell lymphoma:1||Docetaxel:1||Documents:1||Dose modification:1||Drugrelated side effects and adverse reactions:1||Elderly patients:1||End of life:1||Endoflife:1||Epidermal growth factor receptor:1||ErbB2 receptor:1||Erlotinib:1||Ethanol:1||Ethnic groups:1||Eupatilin:1||FDGPET:1||Gastric cancer:1||Gastrointestinal stromal tumor:1||Gefitinib:1||Grade:1||Growth inhibition:1||Hemangiopericytoma:1||Hematopoietic stem cell transplantation:1||Hemorrhage:1||Hereditary spherocytosis:1||Histology:1||Hodgkin&apos:1||Hormonal receptor:1||Hospices:1||Human epidermal growth factor receptor 2:1||Hypoglycemia:1||IgA nephropathy:1||Imatinib:1||International Prognostic Index:1||Invasion:1||Korea:1||Leukemia:1||Lifesustaining treatment decisions law:1||Lymphoplasmacytic lymphoma:1||Maintenance therapy:1||Mediastinal large Bcell lymphoma:1||Metastasis:1||Molecular diagnosis:1||Molecular response:1||Myeloproliferative neoplasm:1||Neoplasm:1||Neoplasms:1||Nomogram:1||NonHodgkin&apos:1||Nutritional assessment:1||Opium dependence:1||Outcome:1||Ovarian epithelial carcinoma:1||Paranasal sinusitis:1||Partial response:1||Patient selection:1||Peripheral Tcell lymphoma:1||Polycythemia vera:1||Prognostic factor:1||Quality of life:1||RBC membrane disorder:1||Refractory symptoms:1||Relapse:1||Rituximab:1||Sedation:1||Sedatives:1||Simplified Nutritional Appetite Questionnaire:1||Skin changes:1||Sodium metaarsenite:1||Soft tissue infiltration:1||Sorafenib:1||Stomach neoplasm:1||Stomach neoplasms:1||TNM stage:1||Telomere:1||Terminal care:1||Thrombocythemia:1||Thrombosis:1||Trastuzumab:1||Treatment pattern:1||Venous thromboembolism:1||Venous thrombosis:1||Weight loss:1||Western:1||acute myeloid leukemia:1||adjuvant:1||angiotensin II receptor blocker:1||angiotensinconverting enzyme inhibitor:1||antileukemic effect:1||autophagy:1||capecitabine:1||chemotherapy:1||cisplatin:1||cladribine:1||continuous palliative sedation:1||erlotinib:1||gastrectomy:1||gefitinib:1||haematuria:1||haemodialysis:1||hairy cell leukemia:1||head and neck cancer:1||hyperkalaemia:1||intermittent palliative sedation:1||intraductal papillary mucinous neoplasm (IPMN):1||mucin:1||multiple myeloma:1||nonsmall cell lung cancer:1||opioid:1||overall survival:1||oxaliplatin:1||pancreas:1||pseudomyxoma peritonei:1||renal pelvic haematoma:1||sDeath:1||sinusoidal obstruction syndrome:1||sodium metaarsenite:1||stomach neoplasms:1||survival:1||therapy:1||복막 가성점액종:1||아편유사제, 약물의존, 약물중독, 약물 관련 부작용 및 유해반응:1||유두상 점액종양:1||점액:1||5fluorouracil:1||췌장:1||Activating mutation:1||Acute myeloid leukemia:1||Addiction medicine:1||Adenocarcinoma histology:1||Adjuvant chemotherapy:1||Advance directive:1||Advance directives:1||Analgesics:1||AnnArbor Stage:1||Asia:1||Autologous stem cell transplantation:1||BCR/ABL1:1||Bcl2:1||Brain metastasis:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE